Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Rondecabtagene Autoleucel · LYL314

Cell therapy (CAR-T) · Kills target cells, directed at CD19 and CD20 (MS4A1) · developed by Lyell Immunopharma

Phase 3 Most advanced trial
LYEL Developer
2 Registered trials

What is Rondecabtagene Autoleucel?

Rondecabtagene autoleucel is an autologous CAR T-cell therapy engineered to express a chimeric antigen receptor targeting CD19 and CD20. It is designed to selectively kill B-cell malignancies expressing these antigens. The drug is being studied in relapsed and refractory non-Hodgkin lymphoma, including diffuse large B-cell lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
LYL314
Drug type
Cell therapy (CAR-T)
Targets
CD19 (antigen), CD20 (MS4A1) (antigen)
Mechanism
Kills target cells, directed at CD19 and CD20 (MS4A1)
Therapy area
Oncology
Developer
Lyell Immunopharma, Inc. (LYEL)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07188558 Phase 3 Large B-cell Lymphoma Recruiting LYEL
NCT05826535 Phase 1/2 Relapsed Non-Hodgkin Lymphoma Recruiting LYEL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diffuse Large B Cell Lymphoma (DLBCL)Diffuse Large B Cell Lymphoma RefractoryDiffuse Large B Cell Lymphoma RelapsedLarge B-cell LymphomaLymphoma, B-CellNon-Hodgkin LymphomaNon-Hodgkin Lymphoma Refractory/ RelapsedRefractory Non-Hodgkin LymphomaRelapsed Non-Hodgkin Lymphoma

Other drugs acting on CD19 / MS4A1

Blinatumomab FDA approved Inebilizumab FDA approved Loncastuximab tesirine FDA approved AZD5492 Phase 1/2 Budoprutug Phase 1/2 Imvotamab Phase 1/2 MK-1045 Phase 2/3 Odronextamab Phase 2/3 TL011 Phase 1

More from Lyell Immunopharma

IMPT-514 Phase 1/2 LYL273 Phase 1/2 LYL797 Phase 1 LYL845 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the LYEL page.

Follow LYEL, the company behind Rondecabtagene Autoleucel

See LYEL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LYEL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.